You are here

Current Adoption of Composite Indices in Evaluating Rheumatoid Arthritis Patients: An Observational Study

Last updated on April 10, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Torino, , 10128 Italy
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Eighteen years of age or older with diagnosis of RA based on the 1987 American College
of Rheumatology (ACR) criteria and in accordance with local guidelines.

- Patients eligible to anti-TNF therapy

- Patients naïve to anti-TNFa drugs

- Patients with radiography (hands and feet) executed by 6 months before the baseline or
at baseline according to modified Sharp Van der Hejde method [Sharp JT et al. 1985;
Sharp JT. Et al. 1989; Van der Heijde DM et al. 1989] Patients capable of
understanding and completing the questionnaire Patients capable of understanding and
signing an informed consent form

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with tumors

- Patients already included in clinical trials

NCT00793403
Pfizer
Completed
Current Adoption of Composite Indices in Evaluating Rheumatoid Arthritis Patients: An Observational Study

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Chronic Pain, Hip Osteoarthritis, Knee Osteoarthritis
NCT02528188
All Genders
18+
Years
Multiple Sites
Psoriatic Arthritis
NCT01976364
All Genders
18+
Years
Multiple Sites
Current Adoption of Composite Indices in Evaluating Rheumatoid Arthritis Patients: An Observational Study
Current Adoption Of Composite Indices In Evaluating Rheumatoid Arthritis Patients: An Observational Study ("NEW INDICES Study")
This is an observational study of composite indices, including the CLARA (CLinical ARthritis Activity) index, in rheumatoid arthritis (RA) patients in routine clinical practice in Italy in order to evaluate clinical remission and low disease activity. Data will be collected only from patients providing informed consent. In this study we aimed to assess the psychometric properties of a new composite instrument termed CLinical ARthritis Activity (PRO-CLARA) that uses only three PRO measures from among the 7 ACR Core Data Set. We hypothesized that this index would facilitate rapid and easy RA activity assessment in daily routine.
All patients who respond to inclusion/exclusion criteria at baseline will be considered valuable for the analysis.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
primary care clinic
Rheumatoid Arthritis
Other: As per routinary clinical care
As per routine clinical care
Other Name: Observational study
1
As per routine clinical care
Intervention: Other: As per routinary clinical care
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
293
June 2010
June 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Eighteen years of age or older with diagnosis of RA based on the 1987 American College of Rheumatology (ACR) criteria and in accordance with local guidelines.
  • Patients eligible to anti-TNF therapy
  • Patients naïve to anti-TNFa drugs
  • Patients with radiography (hands and feet) executed by 6 months before the baseline or at baseline according to modified Sharp Van der Hejde method [Sharp JT et al. 1985; Sharp JT. Et al. 1989; Van der Heijde DM et al. 1989] Patients capable of understanding and completing the questionnaire Patients capable of understanding and signing an informed consent form

Exclusion Criteria:

  • Patients with tumors
  • Patients already included in clinical trials
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Italy
 
 
NCT00793403
0881A1-102317
0881A-102317 ; B1801118
Yes
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2012

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now